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The transcription factor Pax6 regulates multiple aspects of central nervous system (CNS) development. At the cellular level, the Pax6 mutation
was reported to affect homophilic and heterophilic cellular adhesion, neuron polarity and neurite outgrowth. These abnormalities were observed in
multiple regions of Pax6-mutant CNS, suggesting a common function for Pax6 in regulating cytoskeletal dynamics. However, target genes
mediating Pax6 function in cytoskeletal dynamics remain largely unknown. Using DNA microarrays, we identified delta-catenin (δ-catenin /
neurojugin) as a potential direct target of Pax6 in the CNS. δ-catenin encodes a large cytoskeletal protein that localizes at adherens junction in the
CNS and that can modulate neurite outgrowth and N-cadherin turnover. δ-catenin was found to be co-expressed with Pax6 in several regions of
the developing CNS. In Pax6 mutant embryos, δ-catenin expression was severely reduced in the optic vesicle neural ectoderm, in the ventricular
zone of the neocortex and in the external granule layer of the cerebellum. We identified a Pax6 binding site in δ-catenin promoter that is conserved
between mice and humans and which is effectively bound by Pax6 in vitro. Our results suggest that Pax6 regulates δ-catenin expression during
CNS development in mice.
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Homeobox transcription factors share a conserved DNA-
binding motif allowing recognition of target genes and have
been implicated in the regulation of morphogenesis and pattern
formation in vertebrates and insects (Chalepakis et al., 1991;
Goulding et al., 1991; Joyner, 1996). In the anterior neural plate
of mouse embryos, overlapping expression patterns of the
homeobox genes Pax6, Six3, Rx and Lhx2 delimit the
presumptive retina field, consistent with the findings that the
vertebrate retina originates from this region (Couly and Le
Douarin, 1988; Walther and Gruss, 1991; Oliver and Gruss,
1997; Oliver et al., 1995; Mathers et al., 1997; Porter et al.,
1997). At the morphological level, retinas arise from two
bilateral invaginations of the ventral forebrain's neural ecto-⁎ Corresponding author. Fax: +1 514 252 3569.
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The optic vesicle contains all the precursor cells from which the
mature neural retina and retinal pigmented epithelium are
derived. The surface ectoderm is induced by contact with the
optic vesicle to form the lens placode, which ultimately gives
rise to the solid lens (Oliver and Gruss, 1997).
The paired-box- and homeobox-containing transcription
factor Pax6 has been used as a prototype to understand the
basic mechanisms of eye development in metazoans. Pax6
mutations, which are semi-dominant, result in the small eye
phenotype in mice and in Aniridia in humans (Hill et al., 1991;
Ton et al., 1991). Aniridia is characterized by hypoplasia of the
iris, cataract formation and glaucoma and progressive vision
impairment (Ton et al., 1991). Mice, humans and flies carrying
homozygous mutations in Pax6 are eyeless and display severe
brain malformations (Hogan et al., 1986; Glaser et al., 1994;
Quiring et al., 1994). Conversely, over-expression of Pax6 in
flies or frog embryos results in the formation of ectopic eyes,
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regulator of eye development in multi-cellular organisms”
(Halder et al., 1995; Chow et al., 1999; Gehring and Kazuho,
1999). In the mouse, Pax6-null embryos form an optic vesicle
that arrests in development prior to the optic cup stage (Grindley
et al., 1995). Chimera aggregation studies revealed a cell-
autonomous function for Pax6 in cellular adhesion and
proximo-distal patterning of the optic vesicle while grafting
experiments showed a cell-autonomous requirement for Pax6 in
lens placode formation (Fujiwara et al., 1994; Quinn et al.,
1996; Collinson et al., 2000). These results are consistent with
the expression of Pax6 at the earliest stages of eye surface
ectoderm and neural ectoderm formation (Walther and Gruss,
1991). More recently, conditional mutagenesis of Pax6 in the
eye surface ectoderm at e9.5 revealed an unexpected indepen-
dence between retinal development and lens formation. While
mice that are mutant for Pax6 exclusively in the lens
primordium fail to develop a lens placode, they nevertheless
develop a fully grown, differentiated and laminated retina
(Ashery-Padan et al., 2000). Therefore, the eye developmental
arrest observed in Pax6 mutants could be attributed to an
autonomous function for Pax6 during optic vesicle growth.
Alternately, Pax6 may mediate functions in the lens ectoderm
prior to e9.5 that are required for normal optic vesicle growth.
Conditional mutagenesis of Pax6 beginning at e10.5 in the
embryonic retina demonstrated that Pax6 is also required at
later stages of retinogenesis to control the multipotent state of
retinal progenitor cells (Marquardt et al., 2001).
In addition to its central function in eye development, Pax6
also plays multiple roles in the patterning and maturation of
other CNS structures, including the forebrain, cerebellum and
spinal cord. Throughout the CNS, multiple evidence suggests
that Pax6 controls cell adhesion properties as well as neuron
polarity, migration and axonal sprouting. In the optic vesicle of
Pax6 mutant embryos, homophilic cellular adhesion and tissue
adhesion to surface ectoderm are defective in a cell-autonomous
manner (Collinson et al., 2000). This suggests that Pax6 controls
the transcription of genes regulating the cytoskeleton. In the
neocortex and cerebellum of Pax6 mutants, neocortical radial
glia and cerebellar granule cells exhibit polarity anomalies, again
suggesting cytoskeletal defects (Stoykova et al., 1997; Gotz et
al., 1998; Engelkamp et al., 1999; Yamasaki et al., 2001;
Andrews and Mastick, 2003). We previously reported on the
identification of a downstream target gene of Pax6 in the retinal
primordium and developing forebrain using a large-scale in situ
hybridization screen (Bernier et al., 2001). In the present study,
we further investigated how Pax6 controls CNS development
using DNA microarray in order to identify new target genes. We
report on the isolation of a candidate target gene, δ-catenin,
which maymediate some of Pax6 functions in neurite outgrowth
and synapse connection in the developing CNS.
Materials and methods
Animals
Adult mice from the albino CD1 strain were purchased from Charles River
(St-Constant, Qc., Canada). Pax6mutant mice are a gift from Peter Gruss (Max-Planck Institute, Goettingen). Pax6 mutant mice and embryos were genotyped
accordingly to St-Onge (St-Onge et al., 1997) and using LacZ staining in
complementation. Embryonic stage was determined according to the time of
vaginal plug.
Immunofluorescence
Embryos were fixed in 4% PFA/PBS for 1 h, washed in PBS and
equilibrated overnight at 4°C in 30% sucrose/PBS. Samples were then immersed
in Cryomatrix solution (Shandon, Pittsburgh) and snap frozen in liquid nitrogen.
Cryosections were performed at 7 μm and air dried on slides and then washed
3× with PBS prior to blocking. Tissue sections were blocked in a 1% BSA
(Vector laboratories)/0.1% Tween 20/PBS solution for 1 h and then incubated
with the primary antibodies overnight at 4°C in the same solution. After washes
with PBS, the sections were incubated with appropriate secondary antibodies for
1 h at RT. Secondary antibodies are goat anti-rabbit Rhodamine-conjugated
(1:500), goat anti-rabbit FITC-conjugated (1:500) or donkey anti-mouse FITC-
conjugated (1:300) (all from CHEMICON). Sections were mounted with
Vectashield solution containing DAPI (Vector laboratories). Primary antibodies
used were as follows: rabbit anti-Pax6 (1:500), CHEMICON; rabbit anti-β-
galactosidase (1:200), CORTEX BIOCHEM; mouse anti-β-catenin (1:500),
SIGMA; mouse anti-Vinculin (1:200), SIGMA; and mouse anti-δ-catenin, clone
30 (1:100), BD Transduction Laboratories. Fluorescence was visualized using a
LEICA DMRE microscope. Data were acquired using a RETIGA EX digital
camera (QIMAGING, Canada) and the OpenLab 3.1.1 software (OpenLab,
Toronto, Canada).
RNA in situ hybridization
Embryos were dissected in PBS, fixed overnight in 4% paraformaldehyde at
4°C and stored in 100% methanol at −20°C. All the steps of high-stringency
hybridization and washing were done as described previously (Kessel and
Gruss, 1991). Linearized plasmid DNA (1 μg) was used to produce sense and
antisense DIG-labeled RNA probes (Roche) using either T7 or T3 RNA
polymerase (Invitrogen). Riboprobes were purified by ethanol precipitation,
resuspended in TE buffer and filtered in a ProbeQuant G-50 Micro Column
(Amersham Biosciences). Preparations were hybridized with digoxigenin-
labeled RNA probes and visualized with alkaline phosphatase-coupled anti-
digoxigenin antibody (1:2000) (Boehringer) and NBT/BCIP substrate (Boeh-
ringer) at pH 9.5. The DNA fragments used to generate the riboprobes were as
follows: Odf2, Raldh2 and Sfrp-2 cDNA were amplified by RT-PCR based on
the available sequences in the database and cloned into the PCRII vector
(Clontech). δ-catenin cDNA was obtained from R. Zimbelmann (Heidelberg,
Germany).
Microarray
Microarray studies were performed using Affymetrix MG-U44Av2
GeneChips (Affymetrix, Santa Clara, CA), which contain 12,488 probesets
derived from sequence clusters contained in Build 74 of Unigene. The forebrain
of Pax6+/+, Pax6+/LacZ and Pax6LacZ/LacZ littermate embryos at e9.5 was
dissected using tungsten needles. Total RNAwas extracted using Trizol reagent
solution (Invitrogen), including 10 μg of glycogen as carrier, and kept at −80°C
in 70% ETOH. Five RNA samples were pooled for each genotype (Pax6+/+ and
Pax6LacZ/LacZ) and 10 μg of total RNAwas used to produce biotin-labeled cRNA
probes, according to manufacturer's instructions (Affymetrix). Total RNA and
cRNAwere tested on a Bioanalyzer 2100 (Agilent) for quality control. Detailed
protocols for the probe synthesis and hybridization reactions as well as the post-
hybridization washing and staining have been previously described (Novak
et al., 2002). The hybridized arrays were scanned and raw data extracted using
Microarray Analysis Suite 5.0 (MAS5, Affymetrix). The resulting expression
values were analyzed by applying a proportional model to estimate random error
using ArrayStat (Imaging Research Inc., Ontario, Canada). Genes whose
expression differed significantly between Pax6+/+ and Pax6LacZ/LacZ samples
were identified using the t test (p<0.05) corrected using FDR (Benjamini and
Hochberg, 1995) (false error rate=0.05). Probesets with MAS5 designated as
“Absent” in all six samples were excluded to prepare the final list of differentially
expressed genes.
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NIH3T3 cells were transfected with the full-length Pax6 cDNA (Walther
and Gruss, 1991) under the control of the CMV promoter (in pCS2+ vector).
Whole nuclear extracts were analyzed usingWestern blot in order to quantify the
Pax6 protein. Double-stranded oligonucleotides were end-labeled using
polynucleotide kinase and γ-[32P]-ATP. The entire EMSA was essentially
performed as described (Schwarz et al., 2000; Marquardt et al., 2001).
Oligonucleotide position, sequences and Pax6 consensus-binding site core motif
(underlined) are below (Epstein et al., 1994).
(−668) TCCTGTCACGTCTCACCCAGT
(−862) ATACTTTATGCATTCATTTTC
(−1916) AGGCTTGATGCCCTAGTGTAG
(−2398) GATTTCATTTACTCTTTGATGCACTTCGTT
(−2525) TAAATTCACACATCCACTCTG
(−2836) TCAGATGACGTGTCACCTTCT
(−3317) ATCTTTTATGCTTGTTATTAA
(−3848) TATAATTACGCGTGTGTGCAGResults
To isolate novel Pax6 target genes, we performed hybridiza-
tion on an Affymetrix MG-U44Av2 GeneChips that contains
12,488 probesets. By comparing transcript composition
between e9.5 wild type and Pax6LacZ/LacZ forebrains (which
include the optic vesicles), we were able, after 3 independent
hybridization experiments, with 3 independent sets of samples,
to identify differentially expressed genes (Figs. 1A and B) and
(Supplementary data). In total, 438 genes displayed significant
changes in expression levels. Concordant changes were found
for 16 transcripts and statistically significant differences
(ArrayStat proportional error model with FDR correction)
were found for 10 transcripts (Fig. 1A and Supplementary data).
The relatively low number of statistically significant differen-
tially expressed genes identified likely results from the stringent
analytic method used here (i.e. FDR). In addition, the mouse
strain (CD1) as well as variations in embryonic stages or inFig. 1. DNA microarray analysis led to the identification of downstream targets of Pa
experiments. Green box: upregulated in Pax6LacZ/LacZ forebrain; blue box: downregu
analysis of the data set (T1/C1). Dots located in the lower-right portion of the graft c
mount in situ hybridization at e9.5 using Raldh3 or Sfrp2 antisense RNA probes. ov
rhombencephalon; pt: pre-tectum.the micro-dissection procedure could have introduced internal
variations affecting the statistical power of the analysis.
Alternatively, the number of truly differentially expressed
genes in the forebrain of Pax6 mutants may be relatively low
at this stage of development. For example, in a recent study,
only 11 known genes were found to be downregulated in the
telencephalon of Pax6 mutant rats (Arai et al., 2005). For
comparison, over 508 differentially expressed transcripts were
identified in transgenic mice over-expressing Pax6 in the lens
(Chauhan et al., 2002). However, cross comparison of
microarray data with a previous study using Pax6+/− lens
revealed that 13 genes were differentially expressed in both
groups (Chauhan et al., 2002). When compared to our study, we
found that Galactokinase (Fig. 1A) and WNK1 (concordant
changes—Supplementary data) are differentially expressed in
both optic vesicle and lens cells (Chauhan et al., 2002). Because
Pax6 mostly operates as a transcriptional activator, we focused
on genes that were under-expressed in Pax6 mutant samples,
although over-expressed genes are also potentially pertinent to
study. Pax6 was found to be the most differentially expressed
gene in the data set and was used as an internal control in the
microarray experiments. Two genes previously known to be in
part regulated by Pax6 were identified (i.e. Aldh1a3/Raldh3 and
Sfrp2) and differential expression was confirmed by whole
mount RNA in situ hybridization at e9.5 (Figs. 1C and D)
(Suzuki et al., 2000; Kim et al., 2001). Raldh3 was expressed in
the optic vesicle and olfactory placode in wild type embryos and
expression was absent in Pax6 mutants. Sfrp2 expression was
found in the forebrain pre-tectum, hindbrain, rhombencephalon,
spinal cord and eye surface ectoderm in wild type embryos. In
Pax6 mutants, Sfrp2 expression was reduced in most regions of
the CNS, with the exception of the hindbrain, where Pax6 is not
expressed (Walther and Gruss, 1991). Interestingly, Sfrp2
expression was initiated at e10.5 in the optic cup of wild type
embryos and expression was unaltered in the optic vesicle
remnant of Pax6 mutants (data not shown), suggesting that partx6 in the developing forebrain. (A) Significant concordant data set from triplicate
lated in Pax6LacZ/LacZ forebrain; red box: Pax6 internal control. (B) Scatter plot
orrespond to genes that are underexpressed in Pax6LacZ/LacZ samples (C) Whole
: optic vesicle; olf: olfactory placode; se: surface ectoderm; sc: spinal cord; rhc:
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in Pax6 mutants. Remaining new candidate genes include an
Expressed Sequence Tag that encodes for a centrosomal sperm
protein (Outer dense fiber of sperm tails 2 (Odf2)), beta-actin
(β-actin), and δ-catenin/neurojugin (Fig. 1A). Using whole
mount in situ hybridization, we found that Odf2 was
ubiquitously expressed, making it an unlikely Pax6 target
gene. In contrast, δ-catenin is specifically expressed in the
CNS. δ-catenin is a neural-specific member of the Armadillo-
domain subfamily of proteins that includes p120, ARVCF and
p0071 (Paffenholz and Franke, 1997; Zhou et al., 1997; Ho
et al., 2000). These large proteins are characterized by the
presence of several Arm repeats and by their direct interaction
with the cytoplasmic tail of cadherins at adherens junction (Lu
et al., 1999). Adherens junctions are distributed throughout the
lateral cell–cell contacts of epitheliums and neuroepitheliums.
Cadherins are trans-membrane adhesion molecules involved in
actin-based cellular adhesion and migration (Yap et al., 1997).
We performed in situ hybridization on wild type embryos
with a δ-catenin riboprobe. Expression of δ-catenin was
detected at e9.5 in the rhombencephalon, otic placode, optic
vesicle, pre-tectum and forebrain (Fig. 2). In Pax6 mutants,
we observed that δ-catenin expression was abolished in the
optic vesicle, pre-tectum, and rhombencephalon, consistent
with the normal expression of Pax6 in all of these structures
(Fig. 2A) (Walther and Gruss, 1991). To further study this
genetic interaction, we analyzed δ-catenin protein expressionFig. 2. δ-catenin requires Pax6 for expression in the forebrain and
rhombencephalon. Whole mount in situ hybridization at e9.5 using δ-catenin
antisense RNA probe. (A–B) δ-catenin expression is reduced in the optic vesicle
(ov), pretectum (pt), rhombencephalon (rhc) and forebrain (fb) of early (A) and
late stage (B) Pax6LacZ/LacZ embryos. The asterix (*) in the lower panel refers to
a staining artifact.
Fig. 3. δ-catenin localizes at adherens junction in the optic vesicle neural
ectoderm and is absent in Pax6 mutants. (A) δ-catenin immunolocalization in
the optic vesicle of wild type (A and B) and Pax6-null (C and D) embryos at
e9.5. (B) Note the strong immunoreactivity in progenitor cells laying the
ventricular surface (arrowheads). (E–H) β-catenin and Vinculin are localized to
adherens junction. (G and H) Note the localization of Vinculin to apical
membrane junctions (arrowheads in the inset) in wild type but not in Pax6
mutant embryos (inset). ne: neuroepithelium; se: surface ectoderm. (A, C and
E–H) Scale bars: 50 μm. (B and D) are magnifications of (A and C),
respectively.in the optic vesicle. Using a specific monoclonal antibody, we
found by immunofluorescence that δ-catenin was highly
expressed in the neural ectoderm, especially in neuroepithelial
progenitor cells located at the ventricular zone (Figs. 3A and
B). This antibody was previously shown to be highly specific
for δ-catenin (Martinez et al., 2003; Israely et al., 2004).
Neuroepithelial progenitor cells have nuclei with typical
“butterfly” morphology, which is characteristic of metaphase
chromosomes (as visualized with DAPI staining). The
δ-catenin antibody strongly decorated cytoplasmic membranes
at the level of the cell body and of the radial process. In Pax6
mutant optic vesicles, δ-catenin labeling was nearly abolished
Fig. 4. δ-catenin is expressed in Pax6-positive radial glial cells in the neocortex
of wild type embryos and is severely reduced in LacZ-positive progenitor cells
of Pax6 mutants. (A–C). δ-catenin co-localized with Pax6 in the ventricular
zone (vz) (arrowheads) and in some cells of the lateral ganglionic eminence
(lge). (D–F) δ-catenin expression is severely reduced in the ventricular zone
(arrowheads) and in some regions of the ganglionic eminence. Scale bar:
100 μm.
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relationship between Pax6 and δ-catenin expression, we
performed double-labeling experiments on e9.5 WT and Pax6
mutant embryos with Pax6/δ-catenin and LacZ/δ-catenin
antibodies. On horizontal sections of the head, we observed
that Pax6 and δ-catenin were co-expressed in the optic vesicles
and forebrain of WT embryos. In contrast to Pax6, δ-catenin
was also detected in the midbrain and hindbrain neural
ectoderm. In Pax6 mutants, labeling for LacZ was observed
in the optic vesicles and forebrain and δ-catenin expression was
reduced in these same brain regions (Supplementary Fig. 1). To
test whether loss of δ-catenin expression in the optic vesicle of
Pax6 mutants was unique or the consequence of a general defect
in adherens junction formation, we tested the expression of two
additional proteins that also localize at adherens junction i.e. β-
catenin and Vinculin (Jamora and Fuchs, 2002; Li and
Sakaguchi, 2002). In Pax6 mutant embryos, β-catenin and
Vinculin expression in the optic vesicle neural ectoderm was
comparable to wild type littermates (Figs. 3E–H). In both wild
type and mutant samples, β-catenin and Vinculin localized to
cell–cell contacts of the neural ectoderm (i.e. adherens
junction). Notably however, Vinculin localization to apical
membrane junctions, which are facing the ventricular zone of
the optic vesicle neural ectoderm, was not observed in Pax6
mutant embryos (Figs. 3G and H). This suggests that apical
membrane junctions are not present or that localization of
Vinculin to these junctional complexes is defective in the optic
vesicle of Pax6 mutants (Watabe-Uchida et al., 1998). Together
with the above RNA expression studies, these results suggested
that δ-catenin expression in the optic vesicle was under the
control of Pax6 activity.
In addition to the eye, Pax6 is also highly expressed in the
developing brain, especially in the neocortex and external
granule layer of the cerebellum (Gotz et al., 1998; Engelkamp
et al., 1999). Notably, previous reports indicated that δ-catenin
is also expressed in these brain regions (Ho et al., 2000).
Therefore, we investigated whether δ-catenin might depend on
Pax6 for expression in other regions of the CNS. In the
neocortex at e12.5, δ-catenin expression was found to be
predominant in the ventricular zone and in the lateral
ganglionic eminence (Fig. 4A). By comparison, Pax6 was
also detected in the ventricular zone but only in a sub-region
adjacent to the lateral ganglionic eminence (Fig. 4B). Both
proteins were expressed in the same cells in these regions (Fig.
4C). In Pax6 mutants, the ventricular zone develops normally
at first (Gotz et al., 1998). Consistently, robust LacZ
expression was found in the ventricular zone, but the
expression was diffuse in the ganglionic eminence (Fig. 4E).
As expected, δ-catenin expression was severely reduced in
cortical regions where it normally co-localizes with Pax6
(Figs. 4D–F). Similarly, we found that Pax6 and δ-catenin
were both expressed in the external granule layer of the
cerebellum (Figs. 5A–C). In Pax6 mutants at e20.5, expres-
sion of δ-catenin was specifically reduced in the external
granule layer (Figs. 5D–F). Reduced expression of δ-catenin
was also observed in other LacZ-positive cells present in the
cerebellum. The observation that Pax6 and δ-catenin areexpressed in the same cells in wild type embryos and that
δ-catenin and LacZ expression are mutually exclusive in Pax6
mutant brains suggests that δ-catenin is highly dependent on
Pax6 for expression in these cell types. In summary, we
found that when Pax6 was co-expressed with δ-catenin in the
CNS, δ-catenin expression was severely reduced in the
corresponding CNS regions of Pax6 mutants. Conversely, in
the CNS regions where Pax6 is not present (i.e. midbrain and
hindbrain neural ectoderm, part of the lateral ganglionic
eminence and part of the cerebellum), δ-catenin expression
was not affected by the Pax6 mutation.
Phylogenetic analysis of conserved DNA sequences within
non-coding regions is a powerful approach to identify
functional gene regulatory elements (Kleinjan et al., 2001).
Therefore, we compared 20 kilo base pairs (kb) present in the
5′ non-coding genomic DNA regions of mouse and human
δ-catenin genes using BLAST (NCBI) and found 8 highly
conserved domains (i.e. >70% of identity) having a co-linear
organization (Fig. 6A). The conserved domains were all located
within 10 kb of genomic DNA proximal to the transcription
start site and TATA box. We analyzed this conserved genomic
region for Pax6 consensus DNA-binding motifs and found 16
putative Pax6 binding sites in mouse δ-catenin (Epstein et al.,
1994). Eight putative Pax6 binding sites identified here and
Fig. 6. Pax6 binds to a DNA element within the δ-catenin promoter region.
(A) Alignment of the 5′ promoter region of mouse and human δ-catenin. Height
conserved domainswere found (black boxes). A single putative Pax6 binding site
present in domain number 6 (Pax6 bs) was conserved between both species. (B)
Alignment of the mouse (m) and human (h) putative Pax6 binding sites and
positions of 4 conserved nucleotides (black bars). The sequence of the mutated
oligonucleotide (Mut) is shown at the bottom and the modified nucleotides are
marked by (*). Underlined nucleotides correspond to the core domain of the
putative Pax6 binding sites. (C) Electro Mobility Shift Assay using either mouse
(m) or human (h) double-stranded oligonucleotides corresponding to the
sequences presented in (B). Retarded bands are marked by (*). The arrowhead
indicates a super-shifted band. ctl: control nuclear extract not containing Pax6; h
Mut: human mutated; ngn2: neurogenin 2.
Fig. 5. δ-catenin is expressed throughout the cerebellum of wild type embryos
and is reduced in the external granule layer of Pax6 mutants. (A–C) δ-catenin
co-localized with Pax6-positive cells in the cerebellum. (D–F) δ-catenin
expression is severely reduced in the external granule layer (egl). Embryos were
analyzed at e20.5. Scale bar: 50 μm.
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degree of homology with the Pax6 consensus DNA-binding
motif, were tested in Electro Mobility Shift Assays (EMSA) for
Pax6 binding (in Materials and methods). Of these, one
particular sequence readily associated with Pax6 protein
extracts in these assays (Figs. 6B and C), while two other
sequences (−668 and −2836) showed weak but specific
association with Pax6-containing nuclear extracts (in Materials
and methods). The mouse Pax6 binding site (−2398) showing
robust association with Pax6-containing nuclear extracts in
EMSAwas localized in a 194 base pairs region that is identical
at 76% between mouse and human δ-catenin promoters (Fig.
6A). The sequence of the mouse Pax6 binding site (−2398)
itself was found to display 80% of identity with the
corresponding human sequence (−2254) (Fig. 6B). By
EMSAs, we found that the corresponding human sequence
(−2254) also effectively associated with Pax6 and that this
association could be prevented by the addition of cold
competitor oligonucleotides (Fig. 6C). The Pax6-binding
sequence identified in δ-catenin was mutated outside the core
consensus binding site at 4 nucleotide positions conservedbetween mouse and human (Fig. 6B). In gel retardation assays,
these mutations completely abolished Pax6 binding (Fig. 6C).
As positive control in gel retardation assays, we used a double-
stranded oligonucleotide corresponding to the very well
conserved Pax6 DNA binding site found in the mouse and
human neurogenin2 promoter regions (Marquardt et al., 2001).
As additional control, we pre-incubated the Pax6 protein
extracts with a polyclonal antibody against Pax6. This resulted
in the disappearance of the oligo–Pax6 protein complex and in
the formation of a super-shift of higher molecular weight,
confirming the specificity of the DNA–protein interaction
complex (Fig. 6C).
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Using DNA microarray hybridization, we have identified δ-
catenin as a target of Pax6 in the CNS. δ-catenin transcript and
protein were found to co-express with Pax6 in the optic vesicle,
neocortex and developing cerebellum and their expression
levels were severely reduced in the CNS of Pax6 mutants.
Notably, Pax6 could effectively and specifically bind a DNA
sequence in δ-catenin promoter that is conserved between
mouse and human.
Is δ-catenin a direct target of Pax6 in the developing CNS?
Because the Pax6 mutation results in defective eye surface
ectoderm specification and lens placode induction, it cannot be
excluded that gene expression differences found in the optic
vesicle of Pax6 mutants are not indirectly caused by these
abnormalities. However, we previously demonstrated that
nearly all optic vesicle markers tested in this context are
unaffected by the Pax6 mutation, suggesting that overall retinal
specification is maintained in the optic vesicle of Pax6 mutants
(Bernier et al., 2001). This notion is also supported by this
study, which revealed a surprisingly low number of differen-
tially expressed genes between wild type and Pax6-null
embryos. Similar to our finding in the optic vesicle, analysis
of Pax6 mutants' cerebellum revealed that from all markers
tested (including Math1, Zic1, Zic2, Netrin, Dcc and Unc5h3),
only Unc5h3 was affected (Engelkamp et al., 1999). This
suggests that CNS specification is not grossly perturbed in Pax6
mutants and that most downregulated genes are direct or
indirect transcriptional targets. In the present study, we found
that δ-catenin expression was highly reduced in 3 distinct
regions of Pax6 mutant CNS and that Pax6 could bind at least
one conserved DNA element within the δ-catenin promoter.
However, it is clear that factors other than Pax6 also control δ-
catenin expression in the CNS since expression was preserved
in several regions outside the Pax6 expression domain. It is also
very likely that several additional Pax6-binding sites contribute
to δ-catenin expression. Since mouse δ-catenin covers over
900 kb of genomic DNA, multiple regulatory elements may lie
within the entire gene (Fig. 6A). Taken together, our results
strongly suggest that Pax6 directly controls δ-catenin expres-
sion in the developing CNS. However, we cannot exclude that
Pax6 action on δ-catenin expression is in fact mediated by an
intermediate transcription factor lying downstream of Pax6.
δ-catenin, cadherins and Rho
Previous investigators had postulated that the Rho GTPase
and RhoA pathways were putative effectors of Pax6 function in
cytoskeletal dynamics of neurons (Yamasaki et al., 2001).
However, upon inactivation of these molecules using chemical
inhibitors, it was found that Rho and RhoA could not be the
effectors of Pax6 activities (Yamasaki et al., 2001). Never-
theless, this study suggested that Pax6 targets and Rho/RhoA
might be linked at the molecular level. Independent studies have
also revealed that R-cadherin expression is reduced in Pax6mutant forebrain and that Pax6-mediated R-cadherin expres-
sion could control growth of pioneer axons (Stoykova et al.,
1997; Andrews and Mastick, 2003). In gain-of-function
expriments, Pax6 was showed to operate mostly as a
transcriptional activator (Chow et al., 1999). Thus, most Pax6
target genes should be inactive upon Pax6 mutation. Following
this rationale, it is remarkable to notice that RhoA inhibition
promotes neurite outgrowth while Pax6 mutation results in
short neurites (Yamasaki et al., 2001). Therefore, Pax6 target
genes should in principle antagonize the RhoA pathway in
cytoskeletal dynamics. Hence, δ-catenin was shown to establish
a balance between neurite elongation and branching, acting at
the interface between cortactin and RhoA (Martinez et al.,
2003). In cell culture experiments, δ-catenin could efficiently
promote neurite elongation and antagonize RhoA activity on
neurite branching (Martinez et al., 2003). δ-catenin also directly
mediates cadherins turnover, and thus bridges cortactin, RhoA
and cadherins in the CNS (Davis et al., 2003). Recently, it was
shown that in the developing neocortex, neurogenin2 (ngn2)
also controls neuronal migration and polarity apparently
through inhibition of RhoA activity. In this study, electropora-
tion of a dominant negative form of RhoA could partially rescue
the neuronal migration defect observed in the neocortex of ngn2
mutants (Hand et al., 2005). Taken together, this suggests that
distinct transcription factors involved in neurogenesis may
cooperate for the regulation of neuron cytoskeletal dynamics
through converging molecular pathways.
Delta-catenin KO mice
If δ-catenin is the sole mediator of Pax6 activity in
cytoskeletal dynamics, δ-catenin inactivation in mice should
then mimic part of the neuronal phenotypes observed in Pax6
mutants. δ-catenin mutant mice are viable and do not present
gross neurological abnormalities (Israely et al., 2004; Kosik et
al., 2005). However, δ-catenin mutant mice have learning
deficits, synaptic defects, motor impairment and reduced
N-cadherin protein expression. Interestingly, this phenotype in
mice supports the link between δ-catenin mutations in human
and the Cri-du-Chat syndrome, a severe form of mental
retardation (Medina et al., 2000). It is also coherent with the
physical interactions of δ-catenin with Presenilin-1, whose gene
mutations result in familial Alzheimer's Disease (Zhou et al.,
1997). These observations are also coherent with δ-catenin
being a Pax6 target gene in the CNS. However, they suggest that
other target genes, probably acting together with δ-catenin or
having a similar function are also mediating Pax6 activity in
neuron cytoskeletal dynamics. The Arm-domain subfamily
includes p120, ARVCF, δ-catenin and p0071. P120 is the most
abundant Arm protein and is essential for cell–cell adhesion in
the epithelium by stabilizing the turnover of all known cadherins
(Davis et al., 2003). Notably, δ-catenin and ARVCF are
functionally redundant with p120 (Davis et al., 2003). Thus,
other Arm-related genes may also be affected by the Pax6
mutation. Alternately, δ-catenin deficiency in Pax6mutants may
synergize with other unrelated molecules that also control
cytoskeletal dynamics, such as small-GTPases. Tissue-specific
654 R.-H. Duparc et al. / Developmental Biology 300 (2006) 647–655alterations in basal transcription levels of β-actin, the constituent
of filamentous actin, may also contribute to the overall
phenotype (see Fig. 1A), although we have not tested whether
β-actin is truly downregulated in Pax6 mutant CNS. In some
instance, a deficiency in the Netrin receptor Unc5h3 may
specifically cooperate with the δ-catenin deficiency in cerebellar
granule cells of Pax6 mutants. However, in contrast to δ-
catenin, Unc5h3 expression was reported to be unaltered in
Pax6 mutants neocortex and optic vesicle (Engelkamp et al.,
1999).
In conclusion, our study provides additional evidences that
Pax6 controls cytoskeletal dynamics in the developing CNS,
and suggest that Pax6 has a function in neurons to promote
neurite elongation and synapse connections through regulation
of δ-catenin expression. Still uncharacterized alterations in
adherens junctions and apical membrane junctions organization
or function may explain several abnormalities found in the CNS
of Pax6 mutants and further work will be required to identify
the full range of target genes mediating Pax6 activity in
cytoskeletal dynamics.
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